MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
-0.26 (-0.26%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close 99.16
Open 99.15
Bid 0.00 x 1100
Ask 0.00 x 1200
Day's Range 98.84 - 99.69
52 Week Range 81.66 - 100.15
Volume 4,412,087
Avg. Volume 5,530,593
Market Cap 132.641B
Beta (3Y Monthly) 0.53
PE Ratio (TTM) 29.00
EPS (TTM) 3.41
Earnings Date Aug 20, 2019
Forward Dividend & Yield 2.00 (2.02%)
Ex-Dividend Date 2019-03-21
1y Target Est 103.67
Trade prices are not sourced from all markets
  • Benzinga 10 hours ago

    Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind

    Medtronic PLC (NYSE: MDT )’s announcement that it is commencing an offer for more than $4 billion in debt securities should help the company manage its tax headwind, according to Morgan Stanley.  The Analyst ...

  • 12 hours ago

    Medtronic to Extinguish Up to $4.17 Billion in Debt

    Medical devices manufacturer retires outstanding senior notes through 2 cash tender offers

  • CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
    Zacks 16 hours ago

    CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?

    While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.

  • Markit 8 days ago

    See what the IHS Markit Score report has to say about Medtronic PLC.

    Medtronic PLC NYSE:MDTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDT are favorable, with net inflows of $9.39 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Company News For Jun 24, 2019
    Zacks 2 days ago

    Company News For Jun 24, 2019

    Companies in the news are: CGC, KMX, MDT and RHT

  • Moody's 2 days ago

    Medtronic Global Holdings S.C.A. -- Moody's assigns A3 to Medtronic's new euro notes offering

    Moody's Investors Service ("Moody's") today assigned A3 ratings to the euro denominated senior unsecured notes offering of Medtronic Global Holdings S.C.A., a guaranteed intermediate holding company subsidiary of Medtronic plc ("Medtronic"). All of Medtronic's existing ratings remain unchanged. Moody's views the note offering and associated tender offer as credit positive for Medtronic.

  • 3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie
    InvestorPlace 2 days ago

    3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie

    Traders were willing to buoy the market up to April's record highs on Thursday of last week, but no more. The S&P 500 lost 0.13% of its value on Friday, leaving most market participants wondering if the surprisingly bullish June to date is nothing more than a mirage.Source: Allan Ajifo via Wikimedia (Modified)Altria Group (NYSE:MO) was arguably the biggest drag, off 4.5% on doubts that its much-lauded Juul e-cigarette brand would be able to secure the needed approval of the Food and Drug Administration when those products have to get the regulatory agency's green lights. Pot stock Canopy Growth (NYSE:CGC) was the bigger disappointment though. It fell more than 8% after investors had a chance to parse the details of Thursday afternoon's quarterly earnings report. Sales of recreational marijuana fell, sequentially, when they're supposed to continue rising on the wake of recent legalization in Canada.Overstock (NASDAQ:OSTK) did more than its part to keep the market in the black, gaining 15% in response to reports that a couple of potential buyers were mulling the purchase of its e-commerce arm, which is being shed so the company can focus on cryptocurrency.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt just wasn't enough. * 10 Best High-Growth Stocks to Buy for Young Investors Headed into Monday's trading, however, it's the stock charts of AbbVie (NYSE:ABBV), Paychex (NASDAQ:PAYX) and Medtronic (NYSE:MDT) that merit the closest looks. Here's why, and what to look for. AbbVie (ABBV)In late April it was noted that AbbVie was being squeezed into the tip of a converging wedge pattern, formed by a horizontal support line that had been holding up since October, and a falling resistance line that extended back to last May's high. Although the odds favored a bullish outcome despite the trajectory, it was clear that anything could happen. Waiting on one side or the other to flinch was the key.We're still waiting. Although ABBV shares slipped below that key floor a couple of times in the meantime, the floor mostly remains intact. Some new falling resistance lines have since come into play, though the old one marked with a dashed blue line remains part of the equation. Either way, we're getting closer to a decision, if only because there's not much room left to meander between support and resistance. Click to Enlarge * The floor, of course, is still the support area right around $77, marked in yellow on both stock charts, though you could make the case that a slightly declining one has since materialized. It's plotted in red. * It became noteworthy again on Friday just because of the amount of bullish volume that materialized. * While the bulls may be pushing again, it's clear they're struggling just to break above the gray 100-day moving average line that has quelled a couple of rally efforts since early April. Medtronic (MDT)Back in March we looked at Medtronic as it was toying with the idea of a major break above a resistance line around $94, plotted in blue on the daily chart. That didn't happen … at least not right away. As it turns out, MDT would have to peel back one more time and then try again. This month's effort did the job.The speed and distance of that move, however, has also spurred concerns that this usually volatile name is already due for some profit-taking again. When one takes a step back and looks at the longer-term view, however, it's clear there's room for a bit more upside until the upper boundary of a major trading range is encountered again. * 7 Top S&P 500 Stocks of 2019 (So Far) Click to Enlarge * The upper part of the weekly chart's bullish trading range is right around $110, but rising. * On that same weekly chart we see a relatively new bullish MACD crossover in conjunction with a push up and off the lower edge of the long-term trading channel, suggesting this effort's got some "oomph." * In the meantime, last week's high of right around $100, marked with a yellow line, shouldn't be taken lightly. That's more or less where Medtronic shares peaked a couple of times in the last part of last year. Paychex (PAYX)Finally, with nothing more than a quick glance at the Paychex chart, it appears the stock is still in an uptrend, though a slowing one. And, perhaps that benign outcome is what lies ahead. Only time will tell.But, given the sheer scope of the rally since late last year, the slowdown is concerning simply because it may point to an outright reversal into a downtrend. The pump for such a pullback is certainly primed. The good news is, we know exactly where the make-or-break lines are, and what they are. Click to Enlarge * It hasn't come into play yet, but at the current rate of things, it will soon. That is, the purple 50-day moving average line at $84.98 may or may not keep PAYX propped up on its next, impending test as support. * Zooming out to the weekly chart we can see just how unusual the past six months have been. Paychex should have rolled over in March somewhere around $79, at the upper boundary of an established trading range. * We have not yet seen a bearish MACD crossunder in the weekly timeframe, but we're getting closer. That will likely coincide with a break below the 50-day average line.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Telecom Stocks to Set on Speed Dial * 6 Stocks to Sell in the Back Half of 2019 * 7 Top S&P 500 Stocks of 2019 (So Far) Compare Brokers The post 3 Big Stock Charts for Monday: Medtronic, Paychex and AbbVie appeared first on InvestorPlace.

  • Medtronic Announces Cash Tender Offers for up to $4.175 Billion of Outstanding Debt Securities Issued by Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A.
    GlobeNewswire 2 days ago

    Medtronic Announces Cash Tender Offers for up to $4.175 Billion of Outstanding Debt Securities Issued by Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A.

    DUBLIN - June 24, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc. ("Medtronic, ...

  • Medtronic (MDT) Up 8.5% Since Last Earnings Report: Can It Continue?
    Zacks 4 days ago

    Medtronic (MDT) Up 8.5% Since Last Earnings Report: Can It Continue?

    Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday
    Investor's Business Daily 5 days ago

    IBD Stock Of The Day: Dexcom Nears Breakout On Medical Device Heyday

    Dexcom is the IBD Stock Of The Day as the medical devices company flirts with a breakout on its tenth straight day of gains. Shares broke out above a buy point briefly and could try again.

  • Here's how much Medtronic spent to buy Epix Therapeutics
    American City Business Journals 5 days ago

    Here's how much Medtronic spent to buy Epix Therapeutics

    Medtronic announced the acquisition of the California maker of cardiac ablation technology in January, but didn't disclose the value of the deal until now.

  • Motley Fool 5 days ago

    Stock Market News: Pot Losses Hit Constellation Brands; Medtronic Delivers Dividends

    Stocks kept gaining ground on Friday morning.

  • 5 days ago

    Medtronic Boosts Its Dividend, Potentially Adding to Strong Returns

    Medtronic declared an 8% dividend increase, potentially boosting the returns of a stock that has performed well in the past year.

  • Near-Term Outlook for Medical Instruments Industry Bleak
    Zacks 5 days ago

    Near-Term Outlook for Medical Instruments Industry Bleak

    Near-Term Outlook for Medical Instruments Industry Bleak

  • 5 days ago

    Medtronic PLC (MDT) Files 10-K for the Fiscal Year Ended on April 30, 2019

    Medtronic PLC (NYSE:MDT) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019.

  • 3 Dividend Aristocrats to Buy and Hold Forever
    Motley Fool 5 days ago

    3 Dividend Aristocrats to Buy and Hold Forever

    Like dividends? You'll love these Dividend Aristocrats, each of which has the wherewithal to keep the dividends flowing for a long time to come.

  • MarketWatch 5 days ago

    Medtronic boosts dividend by 8%

    Medtronic PLC said Friday it will raise its quarterly dividend by 8%, to 54 cents a share from 50 cents a share. The medical technology company's new dividend will be payable July 25 to shareholders of record on July 8. Based on Thursday's stock closing price of $99.26, the new annual dividend rate implies a dividend yield of 2.18%, compared with the yield for the SPDR Health Care Select Sector ETF of 1.51% and the implied yield for the S&P 500 of 1.95%, according to FactSet. Medtronic's stock, which is still inactive in premarket trading, has gained 9.1% year to date through Thursday, while the health care ETF has tacked on 7.8% and the S&P 500 has advanced 17.8%.

  • Medtronic Announces 8 Percent Increase in Cash Dividend
    GlobeNewswire 5 days ago

    Medtronic Announces 8 Percent Increase in Cash Dividend

    June 21, 2019 - The board of directors of Medtronic plc (MDT) today approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share. This would translate into an annual amount of $2.16 per ordinary share, or a dividend per share payout ratio of 41 percent of prior fiscal year non-GAAP diluted earnings per share (EPS). Today`s announcement marks the 42nd consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P 500 Dividend Aristocrats index.

  • 10 ‘Buy-and-Hold’ Stocks to Own Forever
    InvestorPlace 7 days ago

    10 ‘Buy-and-Hold’ Stocks to Own Forever

    [Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Investing to "buy and hold" is trickier than it looks. The increasing pace of technological change means even the most successful, dominant companies have to continually adapt to keep up. Industries like energy, real estate and even consumer products are facing potentially significant long-term changes going forward. In any era, amassing a collection of retirement stocks simply by buying the best companies and holding them for years can be a risky endeavor.General Motors (NYSE:GM) was a classic "widows and orphans" stock until last decade, when GM wound up going bankrupt. United States Steel (NYSE:X) once was a pillar of corporate America and a buy-and-hold stock. GM shares basically haven't moved in a quarter of a century. Polaroid and Eastman Kodak were once blue-chip stocks. Both went bankrupt as cameras changed from film to digital.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut there still are stocks to buy and hold out there that can last forever, while offering dividend income along the way. * 7 Value Stocks to Buy for the Second Half Here are ten such retirement stocks to buy and hold forever.Source: Shutterstock Bank of America (BAC)Dividend Yield: 2.1%It might seem strange to open the list with Bank of America (NYSE:BAC). After all, we're only a bit more than a decade on from the financial crisis. During that crisis, BofA acquisition Countrywide Financial blew up in spectacular fashion, after pioneering many of the risky tactics that led to the bubble and subsequent bust.But this is a different BofA.Net consumer charge-offs hit a decade-long low last year. Its performance on credit metrics is strong. Government regulations have been criticized as slowing growth -- but they've undoubtedly lowered risk as well, even if observers might argue that a better balance is needed.No less than Warren Buffett is now BofA's largest shareholder, through his Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B). And the Oracle of Omaha is fond of saying that his favorite holding period is "forever."That seems likely true for BAC stock as well.Source: Mustafa Khayat Via Flickr Diageo (DEO)Dividend Yield: 2%Change has come to the alcohol industry, with the number of breweries exploding worldwide and new distilleries popping up as well. The brands owned by Diageo (NYSE:DEO) are well-positioned to adapt to shifting tastes.Diageo owns classic brands like Johnnie Walker whisky, Tanqueray gin, Smirnoff vodka, and Harp and Guinness beer, among many others. What most have in common is a timeless quality and worldwide brand recognition. As a result, while beverage giants like Coca-Cola (NYSE:KO) and Anheuser Busch InBev (NYSE:BUD) have struggled with earnings growth, Diageo grew net income by 13.5% in fiscal 2018 and expects consistent growth going forward. * 7 Value Stocks to Buy for the Second Half Yet with a trailing multiple of 26.5, and with a dividend yield of 2%, Diageo stock isn't all that dearly valued. Long-term investors would do well to own DEO and perhaps use the dividends to buy a bottle or two of fine whisky.Source: U.S. Embassy Kyiv Ukraine via Flickr (Modified) Medtronic (MDT)Dividend Yield: 2%In this day and age, the U.S. healthcare market in particular seems potentially volatile. Concerns about increased spending and political battles over the Affordable Care Act create more questions than answers.But even with that uncertainty, Medtronic (NYSE:MDT) isn't going anywhere. The company's devices are an integral part of modern medicine, ranging from pacemakers to stents to bone grafts to imaging systems.Even the risks involved in the sector look priced into MDT. Medtronic's days of double-digit annual growth may well be behind it, but it's not finished increasing earnings or dividends. MDT stock likely isn't finished rising, either.Source: Shutterstock NextEra Energy (NEE)Dividend Yield: 2.4%Utility stocks are among the most common safe, buy-and-hold stocks. NextEra Energy (NYSE:NEE) is now the largest electric utility in the U.S. by market capitalization. That might actually be the only problem with NEE stock.NextEra shares gained 18% year-to-date, and trades just off record highs. Potential valuation concerns aside, NextEra looks like a winner. It serves customers in the southern Florida region, still one of the nation's fastest-growing areas. A 22.6 forward P/E multiple is high for the space but not outlandishly so. And a 2.4% dividend yield provides income along the way. * 7 Dividend Stocks to Buy as the Trade War Reignites Investors looking for value in the space might look for a smaller play like cheaper Dominion Energy (NYSE:D). But it's usually worth paying for quality, and NextEra Energy looks like one of the best utility stocks out there.Source: Blue Genie via Flickr McCormick & CompanyDividend Yield: 1.5%McCormick & Company (NYSE:MKC) is another quality company whose valuation might spook some investors. But MKC stock very rarely is offered cheaply.The company's market leadership in spices and seasonings provides both an impressive moat and protection against economic downturns. MKC stock did dip after the company acquired French's mustard and Frank's RedHot sauce from Reckitt Benckiser (OTCMKTS:RBGLY) at a price that looked a bit high to many investors. But MKC has recovered those gains and then some.Top-line growth for McCormick likely isn't going to be explosive, but it will be steady. The same has been true of MKC stock, which has returned an average of 13% a year over the past decade, including dividends.With continuous cost-cutting initiatives, the contribution from the acquired brands and organic growth (and growth in organic products), MKC still should be able to provide double-digit annual returns going forward as well.Source: Shutterstock Allstate CorpDividend Yield: 2%Allstate Corp (NYSE:ALL) long has used the tagline, "You're in good hands," and it's true for Allstate investors as well. ALL stock has almost quadrupled from late-2011 lows. And there could be more upside to come.After all, Allstate isn't particularly expensive, trading at a 14 P/E. * 7 Value Stocks to Buy for the Second Half Once any short-term worries subside, ALL should resume its march upward.Source: Shutterstock International Flavors & Fragrances (IFF)Dividend Yield: 2%International Flavors & Fragrances (NYSE:IFF) is a company most consumers encounter every day without knowing it and many investors aren't exactly hip to it, either.As its name suggests, the company develops flavors & fragrances across 13 categories, including cosmetics, perfumes, beverages and sweet flavors. Sales and earnings have increased consistently and so has IFF's share price. At a 53 P/E, IFF does look a bit pricey. But, as with McCormick and other stocks on this list, investors should pay for quality.IFF's hidden, but key role, in so many industries, gives it a great deal of protection against both competition and macro factors. Acquisitions and a growing cosmetic additive business both provide room for growth.Consumers may not know IFF, but investors should.Source: Shutterstock Lamb WestonDividend Yield: 1.4%Lamb Weston (NYSE:LW) was spun off from Conagra Brands (NYSE:CAG) last year. Lamb Weston is the No. 1 potato producer in the United States. In fact, it manufactures the well-known fries at McDonald's (NYSE:MCD), among other restaurant chains.Lamb Weston also has a consumer business (including a small segment that manufactures frozen vegetables), while serving restaurants of all sizes. Health concerns might seem a long-term headwind against the business, but growth has been steady for years, and margins continue to improve.LW is targeting international markets for growth, as French fries have much more limited penetration, while international audiences generally are intrigued by Americanized products.Despite growth and leading market share, LW stock isn't particularly cheap, trading at about 19 times next year's earnings. The company did pick up a fair amount of debt in the CAG spinoff. But it's paying that debt down, which should lower interest expense and boost cash flow going forward. * 7 Value Stocks to Buy for the Second Half With many similar stocks trading at much higher multiples, LW seems to have room for upside. And international growth should offset any health-related concerns in the U.S., should they arise. America's love affair with French fries isn't going to suddenly end, and that should ensure years of stability for Lamb Weston at least.Source: Shutterstock Fortune Brands (FBHS)Dividend Yield: 1.6%Investors are commonly advised to diversify their portfolio. Fortune Brands Home & Security (NYSE:FBHS) has done just that. The company operates in four segments: Cabinets, Plumbing, Doors, and Security. Among its well-known brands are Moen in plumbing, and MasterLock in security.FBHS is more of a cyclical stock than most on this list, and the company no doubt has benefited from the steady, if slow, housing recovery in the U.S. But the company's products also generate relatively stable replacement demand, and a 1.6% dividend yield provides modest, but growing, income.Fortune Brands has been an impressive company since its founding and a solid stock since its 2011 IPO. There may be a bit more volatility here, but that's a worthwhile price to pay for long-term investors. There's enough value in Fortune Brands to ride out any market jitters.Source: Shutterstock Republic ServicesDividend Yield: 1.74%Republic Services (NYSE:RSG) is a bit smaller and likely a lot less well-known than rival Waste Management (NYSE:WM). But in this case, that's not necessarily a bad thing.Republic Services has outgrown its larger competitor in both sales and earnings over the past five years. RSG stock has modestly outperformed WM over the same period as well. Investors appear to believe that will continue, as Republic Services is valued a bit higher than Waste Management, at least based on forward earnings multiples.Both RSG and WM are solid long-term plays. Contracted revenue and steady demand should support both companies for years to come. There's room for further acquisitions in a relatively fragmented space. Republic Services gets the nod here due to slightly better growth and more room for margin improvement. * 7 Value Stocks to Buy for the Second Half But investors looking for safe, stable growth can't go wrong with either RSG or WM.As of this writing, Vince Martin was long MKC. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 10 'Buy-and-Hold' Stocks to Own Forever appeared first on InvestorPlace.

  • Locust Wood Capital Advisers’ Return, AUM, and Holdings
    Insider Monkey 7 days ago

    Locust Wood Capital Advisers’ Return, AUM, and Holdings

    Back in 2002 Stephen J. Errico, a Wall Street investor, who now has more than 30 years of professional investing experience, launched his own NYC-based hedge fund, Locust Wood Capital Advisers. Aside from being the fund's founder he is also its CIO and Controling Principal. Previously, Mr. Errico worked at Morgan Stanley as a portfolio […]

  • 3 Stocks To Buy Ahead of Fed Cuts, Says Goldman Sachs
    TipRanks 9 days ago

    3 Stocks To Buy Ahead of Fed Cuts, Says Goldman Sachs

    All eyes are on the US Federal Reserve right now. On Wednesday, the Fed will reveal whether it decides to slash interest rates or keep them steady at 2.25% - 2.50%. Ahead of the announcement, the general consensus is that the Fed will keep rates steady but set the groundwork for cuts when it next meets in July. “The markets are set up for a cut in July, and if they don’t get it, financial conditions will tighten” Carl Tannenbaum, chief economist at Northern Trust, told Reuters.So how should investors prepare their portfolios going forward? Goldman Sachs has some advice. “If the Fed does cut rates, the S&P 500 usually rallies afterward, with health care and consumer staples outperforming and information technology consistently lagging,” Goldman's chief U.S. equity strategist David Kostin said. The “communication services sector has generated the best relative returns and hit rate of outperformance during the subsequent 3 months (+4 pp, 100%), but has underperformed over a 12-month horizon.”Here we take a closer look at three stocks that fit into these two categories, with 2 healthcare stocks and 1 consumer staples stock. What’s more, all three of these stocks show a ‘Strong Buy’ Street consensus. That’s based on all ratings received over the last three months. Let’s take a closer look at why analysts are so bullish on these stocks now: 1\. Boston Scientific (BSX)Boston Scientific manufactures medical devices used in interventional medical specialties, including everything from needles to pacemakers. Shares are up 14% year-to-date, and over 80% on a three-year basis. Right now, the company is gearing up for its investor day on June 26. This is the first event since 2017- and expectations are high that BSX met or exceeded all of the 2017 and 2018 financial targets. Needham analyst Mike Matson is confident that BSX can sustain high single digit growth over the next few years, and expects it to target organic revenue growth of 7-9% from 2019 to 2022 at the event. “Given BSX’s strong fundamentals (durable high single digit revenue growth, diversified product portfolio, margin expansion potential, etc.), we believe there is potential for upside to consensus estimates and additional multiple expansion and we reiterate our Strong Buy rating” writes Matson. He reiterated his BSX ‘Buy’ rating on June 14 with a $46 price target (14% upside potential). As we can see here the stock has received 9 recent buy ratings and 1 hold rating:View BSX Price Target & Analyst Ratings Detail 2\. Medtronic (MDT)Ireland-based Medtronic is one of the world’s largest medical device makers. Although the company manufactures a wide range of products, most of the hype right now is centered on the MazorX robotic platform. Medtronic snapped up Mazor Robotics for $1.7 billion late last year, and the two companies have now developed the MazorX Stealth Edition robotic guidance platform. The power of the platform is a preoperative planning suite with 3D analytics and tools, which allows surgeons to optimize the surgical process in advance. “Part of MDT’s revenue acceleration thesis depends on the success of MazorX in driving spine share gains” writes Evercore ISI analyst Vijay Kumar. He recently reiterated his Medtronic Buy rating with a $108 price target. “We think MDT’s view of ‘several hundred bps of share gains’ in spine remains a credible thesis given early trends we are seeing. Extrapolating these to general surgery (~80% systems placed for committed implant / consumable volume) lends further credence to why we think robotic surgery could be a big deal for MDT” writes Kumar. The analyst concludes: “We think MDT is the perfect stock for a choppy environment, and should be a core holding given this revenue reacceleration thesis.” That’s alongside Wells Fargo analyst Larry Biegelsen upgrading Medtronic from Hold to Buy with a $110 price target. The analyst comments "We believe MDT is an accelerating growth story trading at a steep discount to its peers."Overall 7 analysts have published buy ratings on MDT in the last three months, with just 2 analysts staying sidelined.View MDT Price Target & Analyst Ratings Detail 3\. Tyson Foods (TSN)While many investors are pouring money into Beyond Foods, it’s also worth taking a closer look at Tyson Foods. This is the world's second largest processor and marketer of chicken, beef, and pork. However the company has also recently branched out into plant-based meat alternatives, including chicken nuggets and patties. Shares have rocketed with a 53% gain so far year-to-date. Boosting prices further was a rating upgrade from Argus Research’s John Staszak. He has a $92 price target on TSN (12% upside potential).Staszak cited a “growing demand for proteins" and notes that Tyson's beef division is experiencing "especially strong demand". Plus the company is working hard to increase prepared foods sales to satisfy the "steady demand and strong margins." And to top of it, Tyson trades at a multiple of just 12.8-times forward earnings, which is below the average large-cap food processor multiple of 18.4-times. It’s also easily towards the low end of Tyson’s own historical 9- to 19-times range. The stock boasts 7 recent bullish calls, with only 1 analyst publishing a Sell rating (Pivotal Research's Timothy Ramey). View TSN Price Target & Analyst Ratings Detail Discover stock ideas from the Street’s best performing analysts here

  • Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam
    Investor's Business Daily 12 days ago

    Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam

    A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.

  • 12 days ago

    Dexcom Looks Like It Can Finally Break Out on the Topside

    For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Kevin Sayer, chairman, president and CEO of Dexcom Inc. The trend-following Moving Average Convergence Divergence (MACD) oscillator just moved above the zero line for an outright buy signal on this time frame.

  • DHL plans to add 50 jobs, invest millions of dollars in Memphis facilities
    American City Business Journals 13 days ago

    DHL plans to add 50 jobs, invest millions of dollars in Memphis facilities

    Logistics firm DHL Supply Chain will expand its medical device and pharmaceutical logistics business in Memphis, bringing about 50 more jobs and $8 million in capital investment.

  • Medtronic Delivers Favorable Outcome on Guardian Connect
    Zacks 15 days ago

    Medtronic Delivers Favorable Outcome on Guardian Connect

    Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.